Sign in
CompletedNo phase

Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification

Key facts

Who runs it
University of Michigan
Where
Ann Arbor, United StatesSee the site
Trial code
Status
Completed
People taking part
44 people enrolled
Started
5 Sept 2024
Ended
18 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Conventional bacterial culture
  • Rapid diagnostic group using mNGS technology
Record updated
11 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with diabetes mellitus
  • Have an infected DFU with a surface area ≥0.5 square centimeter (cm2); o DFU Infection status will be clinically recorded at time of enrollment according to Infectious Disease Society of America (IDSA): mild, moderate, or severe infection
  • Have a hemoglobin A1c[HbA1c] of 12% or less as measured within the last 6 months,
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Who cannot take part

  • Bilateral wound or ulcer
  • Current infection of Coronavirus disease 2019 (COVID19)
  • Uncontrolled blood glucose as demonstrated by a HbA1c of greater than 12%
  • Pregnant or lactating
  • Unable to provide informed consent or are unwilling to participate

Where in United States

  • University of MichiganAnn Arbor, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the role of rapid diagnosis of pathogens in treatment of infection and wound healing in diabetic foot ulcers. This research is studying the use of a new device of people to learn if metagenomic next generation sequencing (mNGS) techniques technology is a feasible tool that can be used to direct targeted antibiotic therapy in infected diabetic foot ulcers.

Read full original descriptionShow less

Participant's tissue will be randomized to usual care tissue collection and cultures (standard of care) or usual care tissue collection and cultures (standard of care) plus metagenomics next generation sequencing (mNGS). The participant's will not be randomized to any treatment (i.e. antibiotic therapy).

The 2 groups in the trial

  • Conventional bacterial cultureExisting treatment, for comparison

    Wound tissue removed will be sent for standard of care evaluation.

  • Conventional bacterial culture plus rapid diagnostic groupTreatment being tested

    Wound tissue removed will be sent for standard of care evaluation as well as rapid diagnostic with metagenomics next generation sequencing (mNGS).

    Treatment: Conventional bacterial culture and Rapid diagnostic group using mNGS technology

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Role of the Microbiome in Diabetic Foot Ulcers
Record updated
11 March 2026